Novartis has signed a four-year strategic collaboration with ProFound Therapeutics, combinigng ProFound's advanced protein identification platform with Novartis’ cardiovascular expertise to discover novel drug targets. The deal features $25 million upfront and milestone payments potentially reaching $750 million per selected target plus tiered royalties. ProFoundry platform’s deep biological data integration enables exploration of previously unknown protein functions pertinent to cardiovascular disease, offering a promising avenue for innovative therapies against a significant global health burden.